Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunoprecipitation [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AHR5062 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-EGFR Antibody Cocktail
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- AHR5072 reacts with an extracellular domain of EGFR. The molecular weight of the antigen is 170kDa (wild type) and 145kDa (vIII variant). This antibody does not block the binding of EGF to EGFR.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 111.6, 199.12, F4, 11E8
- Vial size
- 100 µg
- Concentration
- Lot Dependent
- Storage
- 4° C
Submitted references Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro.
20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter Binding.
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
An evolved Mxe GyrA intein for enhanced production of fusion proteins.
EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.
Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
Sialyl Lewis X modification of the epidermal growth factor receptor regulates receptor function during airway epithelial wound repair.
A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy.
Gray ME, Lee S, McDowell AL, Erskine M, Loh QTM, Grice O, Argyle DJ, Bergkvist GT
Veterinary and comparative oncology 2017 Sep;15(3):890-909
Veterinary and comparative oncology 2017 Sep;15(3):890-909
20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter Binding.
Garcia V, Shkolnik B, Milhau L, Falck JR, Schwartzman ML
The Journal of pharmacology and experimental therapeutics 2016 Mar;356(3):525-33
The Journal of pharmacology and experimental therapeutics 2016 Mar;356(3):525-33
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, Chassat T, Bourette RP, Le Bourhis X, Adriaenssens E
Oncotarget 2015 Oct 6;6(30):29209-23
Oncotarget 2015 Oct 6;6(30):29209-23
An evolved Mxe GyrA intein for enhanced production of fusion proteins.
Marshall CJ, Grosskopf VA, Moehling TJ, Tillotson BJ, Wiepz GJ, Abbott NL, Raines RT, Shusta EV
ACS chemical biology 2015 Feb 20;10(2):527-38
ACS chemical biology 2015 Feb 20;10(2):527-38
EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP
Cancer research 2014 Oct 1;74(19):5572-84
Cancer research 2014 Oct 1;74(19):5572-84
The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.
Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H, Niclou SP
Neuro-oncology 2013 Sep;15(9):1200-11
Neuro-oncology 2013 Sep;15(9):1200-11
Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM
Neoplasia (New York, N.Y.) 2013 Jul;15(7):749-60
Neoplasia (New York, N.Y.) 2013 Jul;15(7):749-60
Sialyl Lewis X modification of the epidermal growth factor receptor regulates receptor function during airway epithelial wound repair.
Allahverdian S, Wang A, Singhera GK, Wong BW, Dorscheid DR
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2010 Apr;40(4):607-18
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2010 Apr;40(4):607-18
A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy.
Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, Olive DM
Analytical biochemistry 2005 Mar 1;338(1):136-42
Analytical biochemistry 2005 Mar 1;338(1):136-42
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was performed using 90% confluent log phase A-431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with EGFR (R19/48MIX) Mouse Monoclonal Antibody (Product # AHR5062) at 1:100 dilution in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membranous localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of EGFR in native human A431 cells using a EGFR monoclonal antibody (Product # AHR5062).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- IP-MS enrichment of EGFR (LFQ intensity): EGFR was enriched 1108-fold from A549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and EGFR antibody (Product # AHR5062). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity.
